(Q53083162)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24428392%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

title

F-18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B-cell lymphoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24428392%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24428392%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Pellegrino Musto

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24428392%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Anna Nardelli

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24428392%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

5

Roberto Guariglia

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24428392%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

2

Giovanna Mansueto

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24428392%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

author name string

Rosj Gallicchio

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24428392%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Daniela Capacchione

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24428392%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Ernesto Soscia

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24428392%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Piernicola Pedicini

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24428392%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Domenico Gattozzi

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24428392%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Giovanni Storto

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24428392%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

publication date

12 February 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24428392%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Haematology

5 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24428392%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

volume

92

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24428392%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24428392%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

page(s)

382-389

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24428392%20AND%20SRC:MED&resulttype=core&format=json

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

5 March 2020

cites work

1 reference

Epidemiology of lymphoid malignancies: last decade update.

21 January 2018

1 reference

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

21 January 2018

1 reference

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

21 January 2018

1 reference

Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma

21 January 2018

1 reference

Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials

21 January 2018

1 reference

Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation.

21 January 2018

1 reference

Assessment of metabolic activity by PET-CT with F-18-FDG in patients with T-cell lymphoma.

21 January 2018

1 reference

Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma

21 January 2018

1 reference

Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma.

21 January 2018

1 reference

Assessment of metabolic response to radioimmunotherapy with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

21 January 2018

1 reference

Positron emission tomographic scans in lymphoma: convention and controversy

21 January 2018

1 reference

High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma.

21 January 2018

1 reference

Standardised uptake value of 18F-FDG on staging PET/CT in newly diagnosed patients with different subtypes of non-Hodgkin's lymphoma.

21 January 2018

1 reference

Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.

21 January 2018

1 reference

Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma.

21 January 2018

1 reference

Statistical methods for assessing agreement between two methods of clinical measurement

21 January 2018

1 reference

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma

21 January 2018

1 reference

The impact of baseline and interim PET/CT parameters on clinical outcome in patients with diffuse large B cell lymphoma

21 January 2018

1 reference

The role of FDG-PET scans in patients with lymphoma

21 January 2018

1 reference

Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma

21 January 2018

1 reference

[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome.

21 January 2018

1 reference

FDG PET/CT of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease

21 January 2018

1 reference

Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake.

21 January 2018

1 reference

Correlating metabolic activity with cellular proliferation in follicular lymphomas.

21 January 2018

1 reference

SUVmax in FDG-PET at the biopsy site correlates with the proliferation potential of tumor cells in non-Hodgkin lymphoma

21 January 2018

1 reference

High maximum standard uptake value (SUVmax) on PET scan is associated with shorter survival in patients with diffuse large B cell lymphoma.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/EJH.12268

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24428392%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference